Last reviewed · How we verify
Enoxaparin (High-dose Group)
Enoxaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa.
Enoxaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa. Used for Acute coronary syndrome (unstable angina and non-ST-elevation myocardial infarction), Deep vein thrombosis and pulmonary embolism prophylaxis and treatment, Acute ST-elevation myocardial infarction.
At a glance
| Generic name | Enoxaparin (High-dose Group) |
|---|---|
| Also known as | Clexane |
| Sponsor | Peking Union Medical College Hospital |
| Drug class | Low-molecular-weight heparin (LMWH) |
| Target | Antithrombin III (enhancer); Coagulation factors Xa and IIa (indirect targets) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Enoxaparin binds to and potentiates antithrombin III, a natural anticoagulant, leading to inactivation of coagulation factors Xa and IIa. This prevents thrombin generation and fibrin clot formation. The high-dose formulation is used in acute clinical settings requiring rapid and sustained anticoagulation.
Approved indications
- Acute coronary syndrome (unstable angina and non-ST-elevation myocardial infarction)
- Deep vein thrombosis and pulmonary embolism prophylaxis and treatment
- Acute ST-elevation myocardial infarction
Common side effects
- Bleeding
- Thrombocytopenia
- Injection site hematoma
- Elevated transaminases
Key clinical trials
- A Clinical Study of SHR-2004 Injection in Preventing Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty (PHASE3)
- SHR-2004 for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty (PHASE2)
- Comparison of the Risk of Venous Thromboembolism (i.e., Blood Clots in the Veins) and Bleeding Events in a Population of Obese Patients Receiving Higher-Dose or Extended-Duration Versus Conventional-Dose or Conventional-Duration of Prophylaxis (i.e., Preventive Treatment) With Enoxaparin
- Prolonged Hypercoagulability Following Major Liver Resection for Malignancy (PHASE3)
- LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients (PHASE1)
- Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention (OPTIENOX-PCI) (PHASE4)
- ANTIcoagulation in Severe COVID-19 Patients (PHASE2)
- Sildenafil Citrate Added to Low Molecular Weight Heparin and Low Dose Aspirin in High-risk Pregnancy
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Enoxaparin (High-dose Group) CI brief — competitive landscape report
- Enoxaparin (High-dose Group) updates RSS · CI watch RSS
- Peking Union Medical College Hospital portfolio CI